Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Prostate specific antigen testing among the elderly--when to stop?

Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, Trock BJ, Metter EJ.

J Urol. 2009 Apr;181(4):1606-14; discussion 1613-4. doi: 10.1016/j.juro.2008.11.117.

2.

Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging.

Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB.

Urology. 2001 Sep;58(3):411-6.

PMID:
11549490
3.

Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.

Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD.

JAMA. 1997 May 14;277(18):1456-60.

PMID:
9145718
4.

Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.

Loeb S, Nadler RB, Roehl KA, Antenor JA, Catalona WJ.

J Urol. 2007 May;177(5):1745-8.

PMID:
17437803
5.

Prevalence of prostate specific antigen testing for prostate cancer in elderly men.

Dyche DJ, Ness J, West M, Allareddy V, Konety BR.

J Urol. 2006 Jun;175(6):2078-82.

PMID:
16697807
6.

Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.

Berger AP, Deibl M, Steiner H, Bektic J, Pelzer A, Spranger R, Klocker H, Bartsch G, Horninger W.

Prostate. 2005 Aug 1;64(3):240-5.

PMID:
15712213
7.

Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.

D'Amico AV, Renshaw AA, Sussman B, Chen MH.

JAMA. 2005 Jul 27;294(4):440-7.

PMID:
16046650
8.
9.

Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.

Moul JW, Sun L, Hotaling JM, Fitzsimons NJ, Polascik TJ, Robertson CN, Dahm P, Anscher MS, Mouraviev V, Pappas PA, Albala DM.

J Urol. 2007 Feb;177(2):499-503; discussion 503-4.

PMID:
17222618
10.

Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk.

Tang P, Sun L, Uhlman MA, Robertson CN, Polascik TJ, Albala DM, Donatucci CF, Moul JW.

J Urol. 2010 Mar;183(3):946-50. doi: 10.1016/j.juro.2009.11.021.

PMID:
20083275
11.

Prostate-specific antigen testing of older men.

Carter HB, Landis PK, Metter EJ, Fleisher LA, Pearson JD.

J Natl Cancer Inst. 1999 Oct 20;91(20):1733-7.

12.

Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.

D'Amico AV, Hui-Chen M, Renshaw AA, Sussman B, Roehl KA, Catalona WJ.

J Urol. 2006 Dec;176(6 Pt 2):S11-5.

PMID:
17084157
13.

Prostate cancer risk assessment program: a 10-year update of cancer detection.

Giri VN, Beebe-Dimmer J, Buyyounouski M, Konski A, Feigenberg SJ, Uzzo RG, Hanks G, Godwin AK, Chen DY, Gordon R, Cescon T, Raysor S, Watkins-Bruner D.

J Urol. 2007 Nov;178(5):1920-4; discussion 1924.

PMID:
17868726
14.

Prostate specific antigen velocity threshold for predicting prostate cancer in young men.

Loeb S, Roehl KA, Catalona WJ, Nadler RB.

J Urol. 2007 Mar;177(3):899-902.

PMID:
17296371
15.

Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.

Sun L, Caire AA, Robertson CN, George DJ, Polascik TJ, Maloney KE, Walther PJ, Stackhouse DA, Lack BD, Albala DM, Moul JW.

J Urol. 2009 Nov;182(5):2242-8. doi: 10.1016/j.juro.2009.07.034.

PMID:
19758616
16.

Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.

Berger AP, Deibl M, Strasak A, Bektic J, Pelzer AE, Klocker H, Steiner H, Fritsche G, Bartsch G, Horninger W.

Urology. 2007 Jan;69(1):134-8.

PMID:
17270635
17.

Defining increased future risk for prostate cancer: evidence from a population based screening cohort.

Schröder FH, Roobol MJ, Andriole GL, Fleshner N.

J Urol. 2009 Jan;181(1):69-74; discussion 74. doi: 10.1016/j.juro.2008.09.012.

PMID:
19012915
18.
19.

Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.

Meeks JJ, Thaxton CS, Loeb S, Roehl KA, Helfand BT, Catalona WJ.

J Urol. 2008 Apr;179(4):1340-3. doi: 10.1016/j.juro.2007.11.068.

PMID:
18289590
20.

Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging.

Wright EJ, Fang J, Metter EJ, Partin AW, Landis P, Chan D, Carter H.

J Urol. 2002 Jun;167(6):2484-7; discussion 2487-8.

PMID:
11992063

Supplemental Content

Support Center